A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis.
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2014
At a glance
- Drugs Decitabine (Primary) ; Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions
- 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Sep 2006 New trial record.